FDA Confirms NMN Dietary Supplement Status in 2025: A Win for Consumers and the Industry

The FDA NMN dietary supplement status 2025 update marks a turning point for longevity supplements. Nicotinamide mononucleotide (NMN) has been one of the most researched and talked-about molecules in this space. But in 2022, the FDA suddenly banned NMN from being sold as a dietary supplement in the United States, citing pharmaceutical drug exclusivity rules. This sparked industry-wide pushback, led by the Natural Products Association (NPA).

Now, in a landmark decision, the FDA has officially confirmed that NMN is not excluded from the definition of a dietary supplement. For consumers and companies alike, this is a turning point that restores access to one of the most promising supplements for healthy aging.

Purovitalis is proud to be a member of the NPA and to have contributed financially to support this effort, ensuring NMN remains available to everyone.

In one minute

• The FDA has officially recognized NMN as a dietary supplement in 2025.
• NMN was previously banned due to pharmaceutical drug exclusion rules.
• The Natural Products Association (NPA) challenged the FDA and won.
• Purovitalis, as a proud NPA member, contributed to defending consumer access.

Why did FDA ban NMN in the first place?

In late 2022, the FDA declared that NMN could not be sold as a dietary supplement. The reasoning was tied to the drug exclusion clause of the Dietary Supplement Health and Education Act (DSHEA). This rule prevents ingredients that are already approved (or under investigation) as pharmaceutical drugs from being marketed as supplements.

Pharmaceutical interest in NMN triggered this clause, and the FDA sided with the drug pathway — effectively removing NMN from supplement shelves in the U.S.

This decision shocked both the supplement industry and consumers, as NMN was already widely available, supported by research, and enjoyed a rapidly growing global market.

The role of the NPA and the petition

The ban did not go unchallenged. The Natural Products Association (NPA), together with the Alliance for Natural Health (ANH), filed a formal citizen petition to the FDA. They argued that NMN had a clear history as a dietary supplement and that restricting it would harm consumers.

Dr. Daniel Fabricant, President and CEO of the NPA, stated:

“This is a victory for science, for consumers, and for access to supplements that support healthy aging. We are proud that our efforts have ensured NMN remains available as a dietary supplement.”

This strong stance, backed by member companies and industry allies, applied the necessary pressure on the FDA to reconsider its position.

NMN FDA approval officially a dietary supplement in 2025

On September 29, 2025, the FDA issued an official response to the NPA’s petition. In the letter, the agency clarified that NMN is not excluded from the definition of a dietary supplement.

This effectively reverses the 2022 ban and restores NMN’s legal status as a supplement in the United States.

What this means for consumers and longevity research

This decision is a major win for:

• Consumers – Individuals once again have access to NMN, a supplement linked to energy metabolism, cellular health, and longevity.
• Researchers – Greater supplement availability means more real-world data, supporting further scientific study.
• The supplement industry – The reversal sets a precedent that consumer access and history of use matter in FDA decisions.

With NMN back on the market, innovation in the longevity space is expected to accelerate, giving people more tools to support healthy aging.

Purovitalis’ role in supporting the industry

At Purovitalis, we believe that longevity science should be accessible. That’s why we joined the NPA and financially supported its petition against the FDA ban.

Our CEO, Koen Ridder, shared his thoughts:

“We are very pleased with the FDA’s decision to restore NMN’s supplement status. This means we can continue sharing the benefits of NMN with people worldwide. At Purovitalis, our mission has always been to bring science-backed longevity supplements to consumers, and this ruling allows us to do just that.”